The Effect of Sitagliptin on Brown Adipose Tissue and Whole-body Metabolism in Overweight Pre-diabetic Men
Sitagliptin, marketed as Januvia, is an established anti-diabetic medication with a significant market presence. This study explores its potential to activate brown adipose tissue, thereby enhancing energy expenditure and reducing obesity-related metabolic disorders. If successful, this could expand Sitagliptin's therapeutic indications beyond glycemic control to include obesity management, tapping into the growing market for obesity treatments. The competitive landscape includes other GLP-1 receptor agonists and emerging therapies targeting BAT activation. Diligence is warranted regarding the regulatory pathways for these new indications and the potential for additional patent protections based on novel mechanisms of action.
Indication: Neoplasms, Adipose Tissue
Modality: small molecule
Target: Glucagon-like peptide-1 (GLP-1) receptor agonism leading to brown adipose tissue (BAT) activation.
Sponsor: Ingrid Jazet
Source URL: ClinicalTrials.gov
Source updated: Jul 16, 2018
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Glucagon-like peptide-1 (GLP-1) receptor agonism leading to brown adipose tissue (BAT) activation.
View original source fields
Condition raw: Neoplasms, Adipose Tissue
Condition normalized: Neoplasms, Adipose Tissue
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Glucagon-like peptide-1 (GLP-1) receptor agonism leading to brown adipose tissue (BAT) activation.
Target normalized: Glucagon-like peptide-1 (GLP-1) receptor agonism leading to brown adipose tissue (BAT) activation.